openPR Logo
Press release

Positive Clinical Trials are Responsible for the Growth of Diabetic Foot Ulcer Therapeutics Pipeline | Top Player are GSK, Destiny Pharma plc, Remedor Biomed Ltd, The Janssen Pharmaceutical Companies of Johnson & Johnson, Biotec Pharmacon ASA

06-07-2019 12:18 PM CET | Health & Medicine

Press release from: Pharma Proff

A diabetic foot ulcer is an open sore or wound that occurs in approximately 15% of patients with diabetes and is commonly located in the bottom of the foot. People with diabetes are at higher risk of developing neuropathy as increased blood glucose levels lead to nerve damage. Poor blood circulation, hyperglycemia, and deprived nutrition are some other risk factors associated with the onset of diabetic foot ulcer.

Download the sample report at: https://www.pharmaproff.com/request-sample/1219

Symptoms of diabetic foot ulcer vary from person to person. Some of the commonly reported symptoms include numbness and tingling sensation, skin discoloration, blisters, and red streaks. The disease can be diagnosed by physical examination and imaging techniques including magnetic resonance imaging (MRI), radiography, and bone scan. Treatment of the disease includes surgical procedures such as shaving or excision of bone and the correction of various deformities to remove pressure from the affected area. Moreover, dead skin and tissue removal, blood glucose management, medication, and regular dressings are also help to manage diabetic foot ulcer.

Get the detailed analysis at: https://www.pharmaproff.com/report/diabetic-foot-ulcers-therapeutics-pipeline-analysis

REGRANEX (Janssen Pharmaceuticals Inc.), a topically administered gel, is one of the marketed products indicated for the treatment of diabetic foot ulcer.

According to the research, most of the therapeutic drug candidates are being developed for topical administration. It has been found that topical route of administration is easy to use, non-invasive, and effective method of treatment, and also ensures high level of patient satisfaction.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1219

In November 2018, Destiny Pharma plc and University of Southampton entered into a research collaboration to examine the use of Destiny Pharma plc’s novel XF compounds to prevent, control, and eradicate chronic clinical infections, including diabetic foot ulcer and cystic fibrosis. Similarly, in February 2016, Gemstone Biotherapeutics LLC licensed new wound-healing technology from Johns Hopkins University for the treatment of diabetic foot ulcer.

Some of the key players involved in the development of diabetic foot ulcer therapeutics include GlaxoSmithKline plc, Destiny Pharma plc, FirstString Research Inc., RHEACELL GmbH & Co. KG, Charsire Biotechnology Corp., ASKLEP Inc., Remedor Biomed Ltd., Janssen Pharmaceuticals Inc., and Biotec Pharmacon ASA.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Positive Clinical Trials are Responsible for the Growth of Diabetic Foot Ulcer Therapeutics Pipeline | Top Player are GSK, Destiny Pharma plc, Remedor Biomed Ltd, The Janssen Pharmaceutical Companies of Johnson & Johnson, Biotec Pharmacon ASA here

News-ID: 1767864 • Views: 692

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Destiny

Impetigo Therapeutics- Pipeline Analysis 2018 | Foamix Pharmaceuticals (Nasdaq: …
Impetigo is a common bacterial infection caused by different kinds of bacteria, including streptococcus and staphylococcus. It is a contagious disease and begins with appearance of red sores on any part of the body, which eventually changes to blisters on the body. Download the sample report @ https://www.pharmaproff.com/request-sample/1064 Impetigo is more common in warm and humid weather, is known to easily transmit in crowded settings like schools and day care. Impetigo can
Decode Your Destiny with the Numerology Name Calculator
Burbank, CA – May 25, 2019 - Trying to decipher your future, get a clearer view of your career and love life? Then why not opt for a free personalized Numerology Reading. Numerology Name Calculator, the world’s largest resource for Astrology enthusiasts, uses the lost art of numerology to find out what your name and birth date say about you. Founded in 2017 by Jeffrey Ito, of numerologynamecalculator.com acts a spiritual guide
Mobile Business Intelligence Market technology will shape the destiny: is your c …
Mobile Business Intelligence Market is defined as “Mobile BI is a device comprising both technical and organizational elements that present ancient and/or actual-time facts to its users for evaluation on mobile devices inclusive of smartphones and tablets (now not laptops), to enable effective selection-making and control guide, for the general cause of growing firm overall performance.” business intelligence (BI) refers to computer-based totally techniques utilized in recognizing, digging-out, and analyzing commercial
Lung Infections Market 2017 - 2025 : Insmed Incorporated, Creative Antibiotics S …
Lung Infections Market: Snapshot The treatment for lung infections has conventionally been led by small molecule therapies. These therapies however, were aimed to treat the symptoms of lung infections, rather than the actual cause of the infection. This has led to the emergence of diverse treatment options, which differ in terms of their targets and their action mechanism. Many past cases exist, where a patient has been given a combination
FACE forms and assessments will be digitised with new partner destiny®
FACE Recording and Measuring Systems Ltd are specialists in providing nationally accredited tools for assessment routinely used by tens of thousands of Healthcare and Social Care practitioners on a daily basis. This recent partnership with destiny® means that these forms will be digitised for clinicians to use with a digital pen allowing for optimal productivity. Recent studies have demonstrated a 30% improvement in capacity through the reduction of administration and
Michel Montecrossa releases Single 'American Crossroads' for Obama, re-election …
‘American Crossroads‘ released by Mira Sound Germany on Audio Single and DVD, is Michel Montecrossa’s New-Topical-Song for Obama, re-election and USA destiny. The song and video ‘American Crossroads‘ are available on the Michel Montecrossa Homepage. Michel Montecrossa says about ‘American Crossroads’: “With Obama on his re-election campaign the world has an eye on America’s future and the American crossroads affecting us all. The United States of America are standing on the crossroads